Kadmon Holdings Inc (NASDAQ:KDMN) CEO Harlan Waksal bought 5,000 shares of Kadmon Holdings stock in a transaction on Thursday, August 10th. The shares were bought at an average cost of $2.27 per share, with a total value of $11,350.00. Following the acquisition, the chief executive officer now directly owns 110,747 shares in the company, valued at $251,395.69. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Harlan Waksal also recently made the following trade(s):

  • On Tuesday, August 8th, Harlan Waksal bought 3,707 shares of Kadmon Holdings stock. The shares were bought at an average cost of $2.34 per share, with a total value of $8,674.38.

Shares of Kadmon Holdings Inc (KDMN) traded down 5.15% on Thursday, hitting $2.21. The stock had a trading volume of 164,718 shares. The stock’s market capitalization is $114.58 million. The firm has a 50-day moving average price of $3.12 and a 200-day moving average price of $3.19. Kadmon Holdings Inc has a 52 week low of $2.05 and a 52 week high of $10.48.

Kadmon Holdings (NASDAQ:KDMN) last issued its earnings results on Thursday, August 3rd. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.05. The business had revenue of $3 million for the quarter, compared to the consensus estimate of $3.46 million. The firm’s revenue for the quarter was down 53.1% compared to the same quarter last year. During the same period last year, the business posted ($4.40) EPS. Equities analysts expect that Kadmon Holdings Inc will post ($1.58) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.watchlistnews.com/kadmon-holdings-inc-nasdaqkdmn-ceo-harlan-waksal-buys-5000-shares/1470158.html.

A number of research analysts have weighed in on the company. Piper Jaffray Companies set a $7.00 target price on Kadmon Holdings and gave the company a “buy” rating in a report on Wednesday, August 2nd. ValuEngine lowered Kadmon Holdings from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Zacks Investment Research lowered Kadmon Holdings from a “buy” rating to a “hold” rating and set a $4.25 target price for the company. in a report on Tuesday, June 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon Holdings in a report on Monday, June 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $9.93.

A number of hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC increased its stake in shares of Kadmon Holdings by 134.7% in the first quarter. Perceptive Advisors LLC now owns 5,185,847 shares of the company’s stock valued at $18,772,000 after buying an additional 2,976,190 shares during the period. Macquarie Group Ltd. acquired a new stake in shares of Kadmon Holdings during the fourth quarter valued at about $2,696,000. JPMorgan Chase & Co. increased its stake in shares of Kadmon Holdings by 11,654.8% in the first quarter. JPMorgan Chase & Co. now owns 228,866 shares of the company’s stock valued at $829,000 after buying an additional 226,919 shares during the period. AE Wealth Management LLC acquired a new stake in shares of Kadmon Holdings during the first quarter valued at about $391,000. Finally, Sawtooth Solutions LLC increased its stake in shares of Kadmon Holdings by 396.9% in the second quarter. Sawtooth Solutions LLC now owns 99,649 shares of the company’s stock valued at $388,000 after buying an additional 79,593 shares during the period.

About Kadmon Holdings

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Insider Buying and Selling by Quarter for Kadmon Holdings (NASDAQ:KDMN)

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.